SSG Advises Eiger BioPharmaceuticals in the Sale of Avexitide Program Assets to Amylyx
SSG served as the investment banker to Eiger BioPharmaceuticals in the sale of Avexitide and its related clinical assets to Amylyx. The sale was effectuated through a Chapter 11 Section 363 process in the U.S. Bankruptcy Court for the Northern...
Read moreDetails










